Bleszynski PA, Goldenberg I, Fernandez G, et al. - Given that heart rhythm disturbances can result from alcohol septal ablation (ASA) in hypertrophic cardiomyopathy (HCM) patients, so, researchers assessed the utility of long-term arrhythmia monitoring with an implantable cardiac monitor (ICM) after ASA in this prospective study. Participants were 56 HCM patients undergoing ASA. These patients underwent ICM implant. At 18 months of follow-up, cumulative rate of ICM identified arrhythmic events was 71% in the Kaplan-Meier analysis, with an event rate of 43% occurring within 3 months after ASA. At 18 months, the cumulative rate of ICM identified first atrial fibrillation event was 37%; and the corresponding rate of complete heart block was estimated to be 19%. Overall, findings demonstrated the effectiveness of ICM following ASA for the purpose of capturing clinically actionable arrhythmic events among HCM patients irrespective of patient’s baseline risk factors.